Causeway Capital Management LLC Has $6.91 Million Stock Position in Takeda Pharmaceutical Company Limited (NYSE:TAK)

Causeway Capital Management LLC reduced its stake in shares of Takeda Pharmaceutical Company Limited (NYSE:TAK - Free Report) by 59.3% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 522,030 shares of the company's stock after selling 759,162 shares during the quarter. Causeway Capital Management LLC's holdings in Takeda Pharmaceutical were worth $6,912,000 at the end of the most recent quarter.

Other large investors have also modified their holdings of the company. Public Employees Retirement System of Ohio bought a new stake in shares of Takeda Pharmaceutical during the 3rd quarter worth about $601,000. QRG Capital Management Inc. raised its stake in shares of Takeda Pharmaceutical by 16.8% in the 4th quarter. QRG Capital Management Inc. now owns 329,644 shares of the company's stock worth $4,364,000 after buying an additional 47,490 shares in the last quarter. HighTower Advisors LLC boosted its stake in Takeda Pharmaceutical by 199.5% during the third quarter. HighTower Advisors LLC now owns 122,587 shares of the company's stock valued at $1,744,000 after buying an additional 81,653 shares in the last quarter. Versant Capital Management Inc acquired a new position in Takeda Pharmaceutical during the fourth quarter worth about $26,000. Finally, Franklin Resources Inc. bought a new stake in Takeda Pharmaceutical in the third quarter worth about $244,000. Institutional investors and hedge funds own 9.17% of the company's stock.

Wall Street Analysts Forecast Growth

Separately, Morgan Stanley raised shares of Takeda Pharmaceutical from an "equal weight" rating to an "overweight" rating in a research note on Wednesday, April 2nd.

Takeda Pharmaceutical Trading Up 0.2 %

TAK traded up $0.04 during trading on Friday, reaching $14.69. The company had a trading volume of 1,971,072 shares, compared to its average volume of 1,850,668. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.72 and a current ratio of 1.31. Takeda Pharmaceutical Company Limited has a 12-month low of $12.58 and a 12-month high of $15.37. The company has a market cap of $46.73 billion, a price-to-earnings ratio of 36.71, a PEG ratio of 0.24 and a beta of 0.39. The firm's 50-day simple moving average is $14.54 and its 200 day simple moving average is $13.91.

Takeda Pharmaceutical (NYSE:TAK - Get Free Report) last issued its earnings results on Thursday, January 30th. The company reported $0.42 EPS for the quarter, topping the consensus estimate of $0.34 by $0.08. Takeda Pharmaceutical had a return on equity of 9.39% and a net margin of 4.53%. Equities research analysts anticipate that Takeda Pharmaceutical Company Limited will post 1.64 earnings per share for the current year.

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.